Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

iMAClung

Financiado

Moving cell-based immunotherapies to fight bacterial lung infections into the c...

Moving cell-based immunotherapies to fight bacterial lung infections into the clinics Harnessing the immune system to combat global diseases has introduced a new era in modern medicine. The iMAClung proposal will extend this concept and will pave the way for the first immune cell-based therapy to combat bacterial a... ver más

30/09/2025

MHH

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

MEDIZINISCHE HOCHSCHULE HANNOVER No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-02-08

ERC-2023-POC: ERC PROOF OF CONCEPT GRANTS Objective:Objectives:The ERC Proof of Concept Grants aim at facilitating exploration of the commerci...

I+D

Cerrada hace 1 año

0% 100% 100%

1 Participantes

MHH

150.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

iPSC2Therapy From iPSC Macrophage Biology Towards Regenerative Therapies... 1M€ Cerrado

MacroRhino Deciphering rhinovirus-mediated macrophages impairment throu... 196K€ Cerrado

RYC2018-024374-I Nuevas terapias celulares para tratar enfermedades infeccios... 309K€ Cerrado

PID2020-113910RB-I00 CONDICIONAMIENTO BIOFISICO DE CELULAS MADRE/ESTROMALES MESEN... 218K€ Cerrado

RTI2018-094355-B-I00 SEÑALES ESPECIFICAS DE TEJIDO QUE MODULAN RESPUESTAS TIPO 2... 242K€ Cerrado

EIN2019-103067 IMPACTO DE LAS CELULAS LINFOIDES INNATAS EN LA FISIOPATOLOGI... 2K€ Cerrado

Duración del proyecto: 19 meses Fecha Inicio: 2024-02-08
Fecha Fin: 2025-09-30

Líder del proyecto

MEDIZINISCHE HOCHSCHULE HANNOVER No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 150K€

Descripción del proyecto Harnessing the immune system to combat global diseases has introduced a new era in modern medicine. The iMAClung proposal will extend this concept and will pave the way for the first immune cell-based therapy to combat bacterial airway infections. With more than 2 million deaths around the world in 2020, lower respiratory tract infections are still the deadliest communicable disease with unmet medical need, highlighting the necessity for radical new approaches to develop therapeutic avenues. The iMAClung proposal aims at the adoptive transfer of human macrophages directly into the infected lung and to restore the endogenous alveolar macrophage (AM) cell pool to efficiently resolve bacterial airway infections and to mediate lung regeneration at the same time. iMAClung will harness the unique features of induced pluripotent stem cells (iPSC) to use macrophages (iMonoMac) as a cell-based immunotherapy following the adoptive transfer of these cells directly to the side of pulmonary infection. iMAClung is built upon the pioneering work of the ERC-Stg iPSC2Therapy, in which the anti-bacterial activity of iMonoMac against a variety of pulmonary (myco)bacterial infections has been successfully demonstrated in vivo. In addition, iPSC2Therapy has also successful shown the first scalable production of off-the-shelf iMonoMac using industry compatible bioreactors, which now paves the way for the development of seminal (non)therapeutic concepts. To enable clinical transfer, iMAClung will build a team of medical, scientific and industrial experts, all dedicated to bring iMonoMac into humans. To enter the next stage of the clinical translation pipeline, a path towards the clinics will be developed, which will facilitate subsequent exploitation and transfer into patients. iMAClung will bridge the seminal therapeutic concept from bench to bedside, having broad value for patients, society, medical personal, and the healthcare/biopharmaceutical industry within Europe and beyond.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores